Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
HPE to buy Juniper Networks in $14 billion all-cash deal
‘Fast Money’ traders talk the latest news concerning Hewlett Packard Enterprise buying Juniper Networks.
The ‘last mile’ of disinflation is going to get a lot trickier, says Mohamed El-Erian
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Mohamed El-Erian, Allianz chief economic advisor and president of Queens’ College, Cambridge, joins ‘Squawk Box’ to discuss the latest market trends, what to expect from today’s December CPI data, the impact on the Fed’s rate path decision, and more.
Google’s antitrust probe heats up
European Commission may be preparing for formal case against Google, according to The Wall Street Journal.
Nasdaq CEO: 2023 IPOs performing well should give investors a ‘boost of confidence’
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Adena Friedman, Nasdaq CEO, joins ‘Closing Bell Overtime’ to talk possible IPOs in 2024, market volatility, AI investing and more. 05:04 Wed, Jan 10 20245:28 PM EST
AMD upgraded to outperform
The “Halftime Report” traders debate a bullish call on AMD by Bernstein analyst Stacy Rasgon.
Hopes for ‘accelerated’ stimulus are driving stocks higher: Strategist
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Investors seem to be expecting a “massive” stimulus from the Democratic sweep of Congress, according to Jim Lowell, CIO of Adviser Investments. 00:00 Fri, Jan 8 20212:43 AM EST
